SYNCHRONIZE-MASLD: Survodutide in adults with obesity and at-risk MASLD
Using the efficacy estimand, 84.2% of survodutide participants versus 24.3% with placebo achieved at least 30% liver-fat reduction; mean body-weight change was -12.2% versus -1.0%.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD)
n=216
Using the efficacy estimand, 84.2% of survodutide participants versus 24.3% with placebo achieved at least 30% liver-fat reduction; mean body-weight change was -12.2% versus -1.0%.
48-week duration and recruitment limited to the United States and Spain; findings should not be generalized beyond the studied obesity/MASLD population.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Using the efficacy estimand, 84.2% of survodutide participants versus 24.3% with placebo achieved at least 30% liver-fat reduction; mean body-weight change was -12.2% versus -1.0%.